Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.62 |
| ▸ | BCHE | P06276 | 6/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | PTGES | O14684 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | CPA1 | P15085 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid Methyl Ester SCHEMBL28079722 | 0.90 | MAOB (0.55) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL30211131 | 0.88 | TAAR1 (0.65) | MAOBBCHECYP4F2CYP4A11KMT2A | |
| SCHEMBL21583868 | 0.88 | TAAR1 (0.65) | MAOBBCHECYP4F2CYP4A11KMT2A | |
| SCHEMBL2747423 | 0.88 | TAAR1 (0.65) | MAOBBCHECYP4F2CYP4A11KMT2A | |
| SCHEMBL2747426 | 0.88 | TAAR1 (0.65) | MAOBBCHECYP4F2CYP4A11KMT2A | |
| SCHEMBL25480447 | 0.87 | MAOB (0.63) | MAOBBCHECYP4F2CYP4A11MEN1 | |
| SCHEMBL6624802 | 0.87 | CYP4F2 (0.59) | MAOBBCHECYP4F2CYP4A11MEN1 | |
| SCHEMBL17386027 | 0.87 | CYP4F2 (0.59) | MAOBBCHECYP4F2CYP4A11MEN1 | |
| SCHEMBL10224054 | 0.86 | SIGMAR1 (0.51) | MAOBBCHE | |
| SCHEMBL13228336 | 0.86 | MAOB (0.53) | MAOBBCHECYP4F2CYP4A11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910320-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-04-16 | — | — | EP | claimed |
| WO-2007011065-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-25 | — | — | WO | claimed |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | LIEBER INST INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-10934283-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9891239-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9891239-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9809590-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809590-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| WO-2008121506-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-09 | — | — | WO | disclosed |
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| WO-2008089005-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | WO | disclosed |
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| EP-1910320-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2007011065-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | PNP, UNG, PNPO | MAOB 132/4885BCHE 572/4885CYP4F2 453/4885 |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | MAOB 2920/4885BCHE 3893/4885CYP4F2 3866/4885 |
| US-20080207620-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | MAOB 2108/4885BCHE 1644/4885CYP4F2 41/4885 |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | LTK, MUSK, FGFR1 | MAOB 3803/4885BCHE 2636/4885CYP4F2 2018/4885 |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | COMT, PNMT, HNMT | MAOB 5/4885BCHE 19/4885CYP4F2 422/4885 |
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | MAOB 2503/4885BCHE 1446/4885CYP4F2 90/4885 |
| US-10934283-B2 | COMT inhibiting methods and compositions | COMT, MAOB, MAOA | MAOB 2/4885BCHE 156/4885CYP4F2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.